Vanta Bioscience announces foray into clinical research
Vanta Bioscience announces foray into clinical research

Vanta Bioscience announces foray into clinical research

Amir Shaikh Article rating: 5.0

The company stated that clinical research business will hit top-line from the last quarter of the ongoing financial year. The company is expecting to add a revenue of Rs. 250 crores in the fifth year through clinical research services.

Bank of Baroda surges on strong Q1FY19 results
Bank of  Baroda surges on strong Q1FY19 results

Bank of Baroda surges on strong Q1FY19 results

Rohan Takalkar Article rating: 4.0

 

The net interest income for the quarter increased by 28 per cent yoy and 9.5 per cent qoq to Rs. 4,381 crore in Q1FY19 vs Rs. 3,405 crore in the same period the previous year. The interest income for the quarter rose by 10.3 per cent yoy to Rs. 11,639 crore in Q1FY19.

Aurobindo Pharma receives USFDA Approval for Bivalirudin Injection
Aurobindo Pharma receives USFDA Approval for Bivalirudin Injection

Aurobindo Pharma receives USFDA Approval for Bivalirudin Injection

Shohini Nath Article rating: 5.0

Aurobindo Pharma has received the final approval from the US Food and Drug Administration for Bivalirudin Injection indicated for the use as an anticoagulant in patients. The product will be launched in September 2018. With respect to the news, the shares of Aurobindo soared 2 per cent.

 

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

Shital Jibhe Article rating: 5.0

The markets on July 30, 2018 opened gap up. BSE Sensex is trading at 37,407.49, up by 70.64 points and the Nifty is trading at 11,290.45, up by 12.10 points.

Wockhardt sets-up facility in Middle East, surges by 3.5 per cent
Wockhardt sets-up facility in Middle East, surges by 3.5 per cent

Wockhardt sets-up facility in Middle East, surges by 3.5 per cent

Apurva Joshi Article rating: 5.0

Wockhardt Limited has set-up its first facility in the Middle East for manufacturing of NCEs (New Chemical Entities). It will cater to the global markets through its Dubai arm of its subsidiary Wockhardt Bio AG.

Units of Morepen Labs receives approval for 2 API drugs
Units of Morepen Labs receives approval for 2 API drugs

Units of Morepen Labs receives approval for 2 API drugs

Gayathri Udyawar Article rating: 5.0

The USFDA has accorded twin approvals to the company's bulk drug facilities in Baddi and Masulkhana, in Himachal Pradesh for export to the US market. The stock spiked up by more than 10 per cent on Monday.

Gati shines on talks of acquisition by TVS Logistics
Gati shines on talks of acquisition by TVS Logistics

Gati shines on talks of acquisition by TVS Logistics

Amir Shaikh Article rating: 1.7

Hyderabad-based logistic service provider, Gati Limited surged almost 30 per cent in three trading session amidst news that TVS Logistics is likely to acquire a controlling stake in the company.

RSS
First32643265326632673269327132723273Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR